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Abstract
Background: No treatment to date is available which specifically targets bone formation in ankylosing spondylitis
(AS). Several recent studies have shown that sclerostin (SOST), a Wnt inhibitor specific to osteocytes and
chondrocytes, is down-regulated in AS patients. This suggests Wnt signalling may be upregulated, and application of
exogenous recombinant SOST (rSOST) may inhibit Wnt signalling and slow pathological bone formation.
Methods: The proteoglycan-induced spondylitis (PGISp) mouse model in which we have previously demonstrated
downregulated SOST expression, was used for this study. Mice were injected with 2.5ug rSOST/day for a period of
8 weeks following induction of disease. Axial skeleton disease development was assessed by histology and skeletal
changes examined using DEXA.
Results: rSOST treatment had no effect on peripheral or axial disease development, bone density or disease severity.
Injected rSOST was stable over 8 h and residual levels were evident 24 h after injection, resulting in a cumulative
increase in SOST serum levels over the treatment time course. Immunohistochemical examination of SOST levels
within the joints in non-rSOST treated PGISp mice showed a significant decrease in the percentage of positive
osteocytes in the unaffected joints compared to the affected joints, while no difference was seen in rSOST treated
mice. This suggests that rSOST treatment increases the number of SOST-positive osteocytes in unaffected joints
but not affected joints, despite having no impact on the number of joints affected by disease.
Conclusions: Although not disease-modifying, rSOST treatment did appear to regulate SOST levels in the joints
suggesting biological activity. Further dose response studies are required and SOST may require modifications to
improve its bone targeting ability in order to affect tissue formation to a meaningful level in this model.
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Background
The spondyloarthropathies (SpA) form a class of joint
diseases which specifically affect the vertebral column.
Ankylosing spondylitis (AS), the prototypic form of SpA,
is a chronic inflammatory arthritis of the primarily axial
skeleton. One of the most debilitating aspects of AS is
the progression from inflammation to bone formation,
where inflammation is triggered by an unknown mech-
anism at the site of tendon and ligament attachments to
bone, resulting in enthesitis, followed by the formation
of bony projections (syndesmophytes) which ultim-
ately may join and result in ankylosis. Inflammation
can be well controlled in many patients by anti-TNF
therapy, however ankylosis may still progress [1–4].
Although a recent Cochrane review determined that
the effects of long term high-dose NSAID treatment
on syndesmophyte formation was unclear [5], other recent
studies have indicated chronic high-dose NSAID treat-
ment [6–8] or long-term TNF blockade [3, 9] may be
effective at slowing progression. No treatment to date
has managed to halt or reverse radiographic progres-
sion in AS.
A major factor in the poor treatment options available
for advanced AS is the lack of understanding of the
* Correspondence: gethin.thomas@uq.edu.au
1The University of Queensland Diamantina Institute, Translational Research
Institute, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Full list of author information is available at the end of the article
© 2015 Haynes et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Haynes et al. BMC Musculoskeletal Disorders  (2015) 16:368 
DOI 10.1186/s12891-015-0823-8
molecular mechanisms driving disease progression. Sev-
eral recent studies in both patients and mouse models
have identified the Wingless (Wnt) pathway, key for
bone development and homeostasis, as disturbed in AS.
Sclerostin (SOST) is specifically expressed in osteocytes
and chondrocytes providing skeletal tissue specific inhib-
ition of Wnt signalling. Inactivating mutations in SOST
which lead to increased Wnt signalling result in increased
bone mass and bone strength, as demonstrated in both
mouse models and human disease [10].
SOST’s tissue-specific expression makes it an attractive
therapeutic target in bone disease. In patients with SOST-
inactivating mutations, the only phenotypes which de-
velop are a direct consequence of high bone mass [11].
Antibody therapies to SOST have recently successfully
completed phase 2 clinical trials, demonstrating an in-
crease in bone density and a decrease in bone turnover
markers in osteoporosis patients [12, 13]. In AS, which ex-
hibits excess bone formation and where dysregulated Wnt
signalling has been established, enhancing SOST activity
presents an intriguing therapeutic possibility. To date no
studies have investigated treatment with exogenous SOST
to inhibit bone formation. In this report we have tested
the effects of treatment with recombinant SOST to reduce
osteoproliferation in the proteoglycan-induced spondylitis
(PGISp) mouse model of ankylosing spondylitis.
Methods
Ethics statement
All mice were kept in specific pathogen-free housing
and fed a standard diet, with water ad libitum. The study
was carried out in accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientific
Purposes (7th Edition). The protocol was approved by
the University of Queensland Animal Ethics Committee
(Permit Number: UQDI/PAH/293/12/NHMRC).
Animals
Spondylitis was induced by injecting three month old
female BALB/c IL-4−/− mice with 2 mg human proteo-
glycan extract in 2 mg dimethyldioctadecylammonium
(DDA) 4 times at two week intervals [14, 15]. Peripheral
arthritis presented after the second injection and mice
exhibited axial skeleton ankylosis as described previously
[15, 16].
Recombinant SOST (rSOST) was kindly provided
by Michaela Kneissel (Novartis Pharma AG, Basel,
Switzerland). Human glycosylated sclerostin was pro-
duced in HEK cells and purified using a proprietary
tag. Activity was confirmed by the manufacturer prior to
supply. rSOST injections were initiated at week 6 after
commencement of the study once all four injections of pro-
teoglycan had been administered, and prior to the develop-
ment of arthritis. Eight mice were injected subcutaneously
daily for eight weeks with 2.5 μg of rSOST dissolved in
Dulbecco’s PBS. The control group received only the initial
proteoglycan injections. Peripheral disease was scored daily
in all mice. Scoring was on a scale of 0–4 where 0–3 came
from previously published methods [14]. A score of 4 was
assigned when severe joint stiffness was apparent by greatly
reduced flexion but little swelling in the rear limb joints.
Due to difficulties in accurately ascertaining joint stiffness
in front limbs, only rear leg scores are included in the
analyses. Mice exhibiting no signs of peripheral disease
were removed from the analysis (two mice). Bone dens-
ity was measured using a PIXImus (GE Medical Systems
Lunar, Madison, WI) as described previously [17]. Serum
collection and bone density scanning were carried out im-
mediately prior to the first rSOST injection and after four
and eight weeks of rSOST injections. Mice were sacrificed
after 8 weeks of rSOST injections for histological examin-
ation. Axial disease could not be scored longitudinally as
the spine and pelvis cannot be imaged non-invasively with
sufficient resolution to follow disease from early stages.
Histology
Histological scoring
Intervertebral joints in hematoxylin and eosin (H & E)
stained sections were scored from 0–4, using a validated
scoring system [18]. Only well sectioned joints were
scored; these were defined as joints with a clear nucleus
pulposus and annulus fibrosis, or in the case of diseased
joints, the presence of square vertebrae. The average
joint score was calculated for each section, in order to
compare sections with differing numbers of joints.
Immunohistochemistry
DAB immunohistochemistry of formaldehyde-fixed
paraffin-embedded samples was performed as described
previously [19]. Briefly, samples were rehydrated, blocked
with appropriate sera, and then incubated with primary
antibody. Goat anti-mouse SOST (AF1589, R & D Sys-
tems, Minneapolis, MN USA) at 1:100 was incubated
for 1 h. Sections were then incubated with the appro-
priate biotinylated secondary antibody, followed by strep-
tavidin conjugated tertiary antibody. Signal was developed
using Cardassian DAB chromogen kit (Biocare Medical,
Concord, CA USA) and sections counterstained with acid
hematoxylin (Sigma, St. Louis, MO USA) for three mi-
nutes. Sections were rinsed then left to dry overnight
before mounting in DPX mounting media (Sigma, St.
Louis, MO USA).
IHC quantification
SOST
In PGISp mice, SOST + ve osteocytes were quantified as
described previously [20]. Data was analysed as a per-
centage of SOST + ve osteocytes from the total number
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of osteocytes counted. Data analysis was performed using
GraphPad Prism software, and a t-test used to identify dif-
ferences between groups.
Elisa
To assess the kinetics of rSOST stability in vivo, five
IL4−/− mice were injected with 2.5 μg rSOST and
serum collected 15 min, 1 h, 4 h, 8 h and 24 h after
the initial injection. Serum levels of SOST were mea-
sured by an ELISA which detected both human and
mouse SOST (UCSN Life Sciences, Inc., Wuhan, China).
Results
rSOST injection
Rapid breakdown of subcutaneously administered rSOST
might prevent the accumulation of an efficacious dose in
the mouse. The bioavailability of rSOST in serum was
assessed by ELISA over a 24 h time course (Fig. 1). The
level of SOST was sharply elevated from 15mins after in-
jection and remained elevated after 8 h (Fig. 1). This de-
tected elevation probably reflects an increase in total
circulating SOST caused by the injection of rSOST, ra-
ther than a secondary increase in circulating endogen-
ous mouse Sost, since it is detected as early as 15 min
after injection. Compared to the zero time point, SOST
levels are still slightly elevated 24 h after injection, sug-
gesting rSOST could accumulate with a daily injection
regime.
Circulating SOST levels
After establishing that rSOST was detectably increased
in serum for at least 8 h of the 24 h injection period we
examined if repeated daily injections resulted in a sys-
temic accumulation of SOST. Serum SOST levels were
measured at the start of the study and after four and
eight weeks of rSOST treatment. A sharp drop in serum
SOST levels was seen 4 weeks after the final PG injection.
There was a slight recovery in the control mice by 8 weeks
and this was greater in the rSOST-treated mice but not
significantly so. Previously we have shown that SOST ex-
pression in bones is reduced in PGISp mice [15]. Similarly,
circulating levels of SOST are also reduced in PGISp mice
both 4 and 8 weeks after their final proteoglycan injection,
irrespective of rSOST treatment (Fig. 2).
rSOST effects on disease progression and severity
In PGISp mice, peripheral arthritis precedes axial disease
and can be scored by monitoring paw swelling and stiff-
ness of rear leg joints [14]. Daily treatment with 2.5 μg
of rSOST made no difference to the progression of per-
ipheral disease (Fig. 3).
Axial disease progression was assessed histologically.
Scoring of intervertebral joints stained with haema-
toxylin and eosin showed that rSOST treatment had
no effect on disease severity in the PGISp model
Fig. 1 Elevation of SOST in serum. As observed using ELISA, SOST
elevation in serum was detectable at all time points tested between
15 min and 24 h after rSOST injection
Fig. 2 Serum SOST levels in control and rSOST treated mice. A
decrease in SOST is apparent at both 4 and 8 weeks after the final
proteoglycan injection (0 weeks). # = vs 0 week control, p < 0.05. * = vs
0 week rSOST, p < 0.05
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(Fig. 4a, p = 0.99). The number of intervertebral joints
exhibiting inflammation (score 1 or 2) or ectopic tis-
sue formation (score 3 or 4) is similar between control
mice and rSOST treated mice (Fig. 4b). Both rSOST
treated and PGISp control mice had large numbers of
severely affected intervertebral joints, with significant disc
destruction and large-scale production of excess tissue
(Fig. 4c). Not all joints in every mouse were affected; some
appeared completely normal (Fig. 4d). This is a common
feature of AS, and also of the PGISp mouse model [15].
Fig. 3 Impact of rSOST treatment on peripheral disease progression. There was no difference in the progression of peripheral disease between
SOST treated and control mice. Scoring commenced prior to the first rSOST injection (Day 0). rSOST treated mice in red, control mice in black
Fig. 4 Axial skeleton histology. a No difference in histological scoring was observed between mice receiving rSOST (2.5 μg/day) and mice
receiving no rSOST (Control) (p = 0.99). Joint scores were averaged for each section scored. b Intervertebral joints exhibiting inflammation
(score 1 or 2) or ectopic tissue formation (score 3 or 4) were similar in number between control and rSOST treated mice. c A severely affected joint
from a control mouse. The IVD has been completely destroyed with subsequent mesenchymal cell proliferation and cartilaginous matrix deposition
with chondrocyte expansion evident. d Normal intervertebral joint, no signs of inflammation, disc destruction or excessive tissue production
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rSOST treatment had no effect on the proportion of joints
affected (data not shown).
rSOST effects on bone mineral density
Altered levels of circulating SOST can result in sys-
temic bone density changes, as seen in the SOST-
transgenic mouse, where increased SOST levels lead to
bone loss [11]. Bone density was measured to assess po-
tential systemic bone loss. There was no difference in
total body, spine or femur bone mineral density (BMD)
between rSOST treated and control mice (Fig. 5a-d).
There was also no difference with rSOST treatment at
any of the time points examined (Fig. 5e). The ineffect-
iveness of rSOST injections on axial disease progression
or BMD suggests the exogenous SOST is not affecting
the skeleton.
Wnt inhibitor expression
Immunohistochemistry was used to quantify SOST ex-
pression. SOST expression was observed in osteocytes
and also in chondrocytes resident in calcified cartilage.
There was no difference in the percentage of SOST posi-
tive osteocytes between rSOST treated and untreated
control PGISp mice in severely affected joints (score = 4,
Fig. 6a). However, in control PGISp mice, there was a
significant decrease in the percentage of positive osteo-
cytes in the unaffected joints compared to the affected
joints (p = <0.05, Fig. 6a). There was also an increase in
the percentage of positive osteocytes in the unaffected
joints of rSOST treated mice in comparison to the un-
affected joints of untreated control PGISp mice (p = <0.05
Fig. 6a). This suggests that rSOST treatment increases the
number of SOST-positive osteocytes in unaffected joints
but not affected joints, despite having no impact on the
number of joints affected by disease.
Discussion
No treatment currently available is able to reverse or
significantly slow the excessive bone formation which
occurs in AS. Recent studies have demonstrated that
Wnt signalling appears to be up-regulated in AS evi-
denced by decreased levels of the bone-associated Wnt
Fig. 5 rSOST impact on bone density. No systemic or localized changes in bone density were observed after rSOST treatment. There was
no difference in initial or final bone density between the three groups. a Whole body BMD at the termination of the experiment (p = 0.19). b Terminal
BMD of spine and pelvis only (p = 0.59). c Terminal right femur BMD (p = 0.62). d Initial whole body BMD measurement after four proteoglycan
injections (p = 0.46). e Whole animal BMD by treatment group at each time point (p = 0.7)
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inhibitor SOST in both human and mouse studies
[15, 21, 22]. Inhibiting Wnt signalling through SOST
supplementation therefore presents a potential therapeutic
target for the specific treatment of this bone formation.
However, daily treatment with rSOST did not alter disease
progression or severity in the peripheral joints or axial
skeleton joints of PGISp mice.
There are a number of factors which may have contrib-
uted to the lack of efficacy of rSOST at inhibiting excess
tissue formation in this study, including efficacy of a hu-
man recombinant SOST in mice, low stability of rSOST,
failure of rSOST to reach joints, or insufficient dosage.
Human SOST has previously demonstrated activity in a
mouse system; the human SOST transgenic mouse, in
which a bacterial artificial chromosome (BAC) containing
the human SOST gene was inserted, is osteopenic [11]. In
this model overexpression of human SOST was effective
at blocking Wnt signalling, resulting in a marked decrease
in osteoblast activity and thus bone formation.
Recombinant SOST degradation appeared to be rela-
tively slow in PGISp mice, as circulating SOST levels
were significantly increased 8 h after injection and
remained elevated after 24 h. Further over an 8 week
injection protocol it appeared that circulating levels of
SOST were increasing suggesting an accumulation of
the protein. This suggests that injection of rSOST
might be a viable approach if therapeutic efficacy could
be demonstrated. Alternatively, the circulating SOST
increases might be due to increased endogenous ex-
pression. Unfortunately, the ELISA used did not differ-
entiate between human and mouse SOST isoforms.
rSOST may have been bound to other proteins in the
bloodstream which prevented it from exerting its actions
at the joint. However, changes in SOST levels within the
joints were observed. rSOST treatment increased the
number of SOST positive osteocytes in unaffected joints.
In vitro, application of recombinant human SOST results
in decreased expression of SOST in human pre-osteocyte
cells [23]. However, the same levels of recombinant hu-
man SOST caused increased expression of SOST in less
mature cultures thus application of exogenous human
SOST in our study may have influenced endogenous
mouse SOST levels.
The failure of injected SOST to have any effect on
bone formation in this experiment does not exclude
SOST as a potential therapeutic in AS. There is strong
suggestive evidence from both mouse models and hu-
man patients that regulation of SOST is an important
factor in bone formation in AS. Markedly reduced SOST
expression has been shown both in serum and biopsies
from AS patients [21, 22]. High SOST levels occur in
hTNFtg mice, as TNF-α stimulates SOST expression
[24, 25] but if the mice are treated with Dikkopf-1 neu-
tralising antibodies, which also results in reduced levels of
SOST, spondylitis occurs [24]. Additionally, SOST ex-
pression is downregulated in the intervertebral joints in
proteoglycan induced spondylitis (PGISp) mice [15].
SOST may need to be further stabilized or targeted to
the bone to increase its potency as a treatment. SOST’s
bone specificity in non-pathological situations comes from
its specific expression in osteoblasts and osteocytes rather
than it having any endogenous bone-targeting properties.
One possible strategy is to complex SOST with a bone-
targeting moiety, such as a bisphosphonate, to allow the
specific accumulation of SOST in the bone. This approach
of attaching a therapeutic to a bisphosphonate for bone
Fig. 6 SOST expression in osteocytes. No difference in the percentage of SOST positive osteocytes in affected vertebrae between untreated and
rSOST treated mice. a There was a decrease in SOST expression at unaffected joints, and a significant decrease in unaffected control mice
compared to all other groups (* p <0.05). There was a significant increase in SOST positive cells in the unaffected joints of mice treated
with rSOST in comparison to the unaffected joints of untreated control mice (# p < 0.05). b Example of SOST positive osteocytes (brown
staining, red arrows). A negative osteocyte is also clearly visible (purple staining, blue arrow)
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targeting has previously proven successful in a mouse
model of metastatic breast cancer [26].
Alternatively, the attachment of an FcD10 motif to a
recombinant human alkaline phosphatase protein has
shown success in the treatment of hypophosphatasia
[27, 28]. The FcD10 motif contains the human IgG1 Fc
domain and a deca-aspartate motif. This motif created a
strong affinity for hydroxyapatite while not reducing the
activity of the enzyme. This targeting strategy has been
successful in ameliorating hypomineralization in hypopho-
sphatasia patients where direct infusion or injection of the
alkaline phosphatase enzyme have previously failed [29].
This is the first study to report the injection of rSOST
in a mouse model. There have been very few reports of
in vivo studies targeting the skeleton utilising recombin-
ant proteins. The dosage of 2.5 µg is similar to that used
in previous studies. The lack of efficacy of rSOST to
alter the disease course in treated mice may have there-
fore been a contributed to by an insufficient dosage ad-
ministered. Future studies should investigate the impact
of higher dosages, including safety and toxicity profiling.
Encouragingly, a recent study examining Wnt inhibition
through inhibiting β-catenin function in murine systemic
sclerosis, another mouse model of rheumatic disease, dem-
onstrated efficacy in reducing and reversing the primary
disease symptom of fibrosis. Despite the administration of
the Wnt inhibitors systemically, no other side effects such
as hair loss or gut abnormalities were seen [30].
The aim of this study was to specifically focus on the
potential role of Wnt signalling inhibition in a mouse
model of AS. Current knowledge suggests that Wnt sig-
nalling will play a role in AS through the osteoproliferative
phase of the disease. The PGISp mouse is a good choice
for such a study as it has been well established that this
model exhibits axial osteoproliferation similar to the hu-
man condition. However there are a number of differences
between the PGISp mouse model and AS. Disease in
PGISp mice favours females rather than males and there
is no strong evidence for a significant role for HLA-B27.
A different model could be used to examine the effect of
rSOST on bone formation, such as transgenic HLA-B27
rats which spontaneously develop spondylitis and also ex-
hibit axial osteoproliferation [31]. Alternatively, a non-AS
model could be used, such as the spinal cord injury in-
duced model of neurological heterotopic ossification
where local inflammation leads to ectopic bone formation
[32]. Application of exogenous rSOST in these models
may lead to additional insights into the role and import-
ance of Wnt signalling in pathological bone formation and
how this may be manipulated in a therapeutic setting.
Conclusions
Further studies are required to fully determine if SOST
is an appropriate therapeutic to inhibit bone formation
in AS. Although not disease-modifying, rSOST treat-
ment did appear to regulate SOST levels in the joints
suggesting biological activity. The PGISp mouse model
is a good model of inflammatory bone formation in AS
particularly to examine therapies targeting Wnt signal-
ling. Downregulation of SOST in this model pheno-
copies the downregulation of SOST previously reported
in human patients. Further dose response studies are re-
quired and SOST may require modifications to improve
its bone targeting ability in order to affect tissue forma-
tion to a meaningful level in this model.
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